Developing orphan drugs involves navigating intricate regulatory landscapes, financial risks, and limited clinical data. To ...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, ...

After facing market headwinds in recent years, the biopharma industry finally had some wind at its back in 2024. Jumps in ...

Permanent cloud network AR.IO onramps credit cards for its leading domain name and web-hosting service, ArNS, on the Arweave ...

Icon's balance sheet is sound, with its revenue cyclicality and operating leverage each possessing a medium rating. Icon has historically maintained a fairly conservative balance sheet, and it ended ...

Clinical trials are often conducted at a limited number of hospitals, forcing remote patients to bear high travel burdens and frequently withdraw from trials. Additionally, decentralized trial ...

Cellecta Inc. made remote diagnostics and decentralized clinical trials significantly easier with the launch of its Drivermap Exp assay. The microsampling kit provides a “molecular snapshot” of 19,000 ...

With operations in the Shoppers Drug Mart locations in Canada having concluded as of March 31, 2025, this allows for the ...

Newswise–Most patients with Alzheimer's disease and Alzheimer's disease-related dementias experience the gradual onset and progression of ...

Q1 2025 Earnings Call Transcript April 30, 2025 GeneDx Holdings Corp. beats earnings expectations. Reported EPS is $0.27, expectations were $0.11. Operator: Good day, and thank you for standing by.